Regeneron Pharmaceuticals (REGN) shares were down over 2% in recent Friday trading after multiple media reports said that a US appeals court denied the company's request to block sales of biosimilar versions of its drug Eylea.
The company was seeking to prevent Amgen (AMGN) and others from marketing copy-cat versions of its treatment for wet macular degeneration but the US Court of Appeals for the Federal Circuit upheld an earlier decision to deny Regeneron's motion for patent infringement.
The earlier motion was denied on grounds that the company could not prove Amgen infringed on Regeneron's patents covering a vial containing Eylea, according to reports.
Price: 664.59, Change: -16.02, Percent Change: -2.35
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.